Aditya Bardia, MD, MPH, on Elacestrant vs Standard-of-Care Endocrine Therapy in ER-Positive, HER2-Negative Breast Cancer
2022 San Antonio Breast Cancer Symposium
Aditya Bardia, MD, MPH, of Massachusetts General Hospital, discusses results from the phase III EMERALD trial, the first study to demonstrate improved progression-free survival vs standard of care in estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer with one to two prior lines of endocrine treatment, with or without one line of chemotherapy. This finding applied to all patients in the study, including the subgroup with ESR1 mutations (Abstract GS3-01).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Endocrine therapy with a CDK4/6 inhibitor is the preferred first line treatment for patients with hormone receptor positive metastatic breast cancer, but patients eventually have disease progression. Endocrine resistance could be due to development of mutations in the estrogen receptor, the ESR1 mutations. In the second, third line setting we tend to use Fulvestrant as the endocrine therapy, but Fulvestrant is given as an intramuscular shot and different studies have shown that the duration of response, the median progression-free survival with Fulvestrant in the post-CDK4/6 setting is about two to three months, so clinically, there's an unmet need for better endocrine therapy options for patients with metastatic hormone receptor positive breast cancer.
The EMERALD trial was designed to look at a novel oral selective estrogen receptor degrader SERD called Elacestrant. It was compared with standard endocrine therapy Fulvestrant or choice of aromatase inhibitor depending on what patients received previously. If a patient had received AI plus a CDK4/6 in first line, in the second line setting they could receive Fulvestrant if randomized to the control arm.
The primary endpoint of the trial was progression-free survival in all patients. There was another primary endpoint which was progression-free survival in patients with ESR1 mutant hormone receptor positive metastatic breast cancer. As a reminder, this trial required patients to have received prior CDK4/6 inhibitor so it was in the post-CDK4/6 setting, second/third line setting.
At SABCS 2021 we saw the first results from the EMERALD trial, which demonstrated that Elacestrant was superior to standard of care endocrine therapy. At SABCS 2022 we saw updated results from the EMERALD trial stratified by the duration of prior CDK4/6 inhibitor. The key findings were that the duration of prior CDK4/6 inhibitor was associated with benefit from Elacestrant because if we look at the curves from the EMERALD trial, we see an initial drop and then separation of the curves in favor of Elacestrant. The question was can we identify the endocrine sensitive population because the initial drop is likely endocrine resistant, and then the separation is the endocrine sensitive population. It looks like the duration of prior CDK4/6 inhibitor can help identify the endocrine sensitive population.
For example, in all comers, the median progression-free survival in patients who had a prior CDK4/6 duration of at least 12 months, with Elacestrant the median PFS was close to six months versus about two months with standard endocrine therapy. This was even more pronounced in patients who had ESR1 mutant cancer, where the median PFS was more than eight months with Elacestrant versus about three months with standard endocrine therapy. So in summary, Elacestrant was superior to standard endocrine therapy in the second/third line setting for patients with hormone receptor positive metastatic breast cancer.
Prior duration of CDK4/6 inhibitor was associated with benefit with Elacestrant with a median PFS of more than eight months in patients with mutant ESR1 breast cancer. The drug was, in general, well tolerated. It's an oral drug. Majority of patients were able to continue Elacestrant without discontinuing because of side effects so it provides us an oral option for patients with metastatic hormone receptor positive breast cancer in the second/third line setting.
EMERALD looked at single agent Elacestrant versus standard endocrine therapy. There's a clinical trial called ELEVATE, which would look at Elacestrant in combination with other targeted therapies such as PI3 kinase inhibitor, mTOR inhibitor, CDK4/6 inhibitor. The ELEVATE trial would look at Elacestrant based combinations for patients with hormone receptor positive metastatic breast cancer.
Related Videos
The ASCO Post Staff
Lisa A. Carey, MD, and Joannie M. Ivory, MD, MSPH, both of the University of North Carolina at Chapel Hill, discuss the higher frequency and treatment implications of nonluminal A or high-risk tumors in Black and younger women. In this study, PAM50 and 21-gene assays revealed different demographic patterns by race and age (Abstract PD1-08).
The ASCO Post Staff
Andrea De Censi, MD, PhD, of Italy’s E.O. Ospedali Galliera, discusses phase III findings showing that low-dose tamoxifen (so-called babytam) given for 3 years still significantly prevents recurrences from noninvasive breast cancer after a median of 7 years from treatment cessation. Babytam at 5 mg/d for 3 years significantly lowered recurrence from noninvasive breast cancer at 10 years without “excess” adverse events (Abstract GS4-08).
The ASCO Post Staff
Joseph A. Sparano, MD, of the Tisch Cancer Center at Mount Sinai Health System, discusses long-term clinical outcomes data that continue to show many women with early breast cancer can safely forgo chemotherapy, when guided by the 21-gene recurrence score result. The longer follow-up also showed that recurrences of breast cancer continue to occur years after the original diagnosis, although these recurrences were not prevented by chemotherapy use. Racial disparities were not explained by inequities in social determinants of health or treatment adherence, with Black women at higher risk of early recurrence within the first 5 years of diagnosis, but not later recurrence after 5 years (Abstract GS1-05).
The ASCO Post Staff
Yara Abdou, MD, of the University of North Carolina, discusses results from the RxPONDER SWOG S1007 study, which showed that non-Hispanic Black women with hormone receptor–positive/HER2-negative breast cancer with one to three involved lymph nodes and a recurrence score of ≤ 25 have worse outcomes than non-Hispanic White women. In addition, Black patients were more likely to accept treatment assignment than their White counterparts and were just as likely to remain on estrogen therapy at 6 and 12 months, suggesting that outcome differences may be less likely attributable to lack of treatment compliance within the first year (Abstract GS1-01 ).
The ASCO Post Staff
Erica L. Mayer, MD, PhD, of Dana-Farber Cancer Institute, discusses findings from the PACE study of patients with endocrine- and CDK4/6 inhibitor–pretreated estrogen receptor–positive/HER2-negative metastatic breast cancer who were randomly assigned to fulvestrant alone; fulvestrant and palbociclib; or fulvestrant, palbociclib, and avelumab. Combining palbociclib with fulvestrant beyond disease progression on a prior CDK4/6 inhibitor regimen did not improve progression-free survival compared with fulvestrant alone. A longer progression-free survival when a PD-L1 inhibitor was added to fulvestrant and palbociclib deserves further study. A baseline circulating tumor DNA analysis suggests that the potential benefit of palbociclib after progression on a prior CDK4/6 inhibitor may be influenced by ESR1 or PIK3CA status (Abstract GS3-06).
